Insufficient Impact: Limited Implementation of Federal Regulatory Changes to Methadone and Buprenorphine Access in Arizona During COVID-19-Reference-Cited by-同舟云学术

Insufficient Impact: Limited Implementation of Federal Regulatory Changes to Methadone and Buprenorphine Access in Arizona During COVID-19

Published:2024-04 Issue:2 Volume:3 Page:100177
ISSN:2773-0654
Container-title:AJPM Focus
language:en
Short-container-title:AJPM Focus

Author:

Meyerson Beth E.^ORCID,Bentele Keith G.,Brady Benjamin R.^ORCID,Stavros Nick,Russell Danielle M.,Mahoney Arlene N.^ORCID,Garnett Irene,Jackson Shomari,Garcia Roberto C.,Coles Haley B.,Granillo Brenda,Carter Gregory A.^ORCID

Funder

Foundation for Opioid Response Efforts

Vitalyst Health Foundation

Publisher

Elsevier BV

Reference48 articles.

1. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research;Amato;J Subst Abuse Treat,2005

2. Confronting the stigma of opioid use disorder—and its treatment;Olsen;JAMA,2014

3. Federally qualified health centers can expand rural access to buprenorphine for opioid users in Arizona;Brady;Health Serv Insights,2021

4. Characteristics of U.S. counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder;Haffajee;JAMA Netw Open,2019

5. buprenorphine physician supply: relationship with state-level prescription opioid mortality;Knudsen;Drug Alcohol Depend,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022;Journal of Substance Use and Addiction Treatment;2024-05